We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
GlaxoSmithKline (GSK) was recently hit with an FDA warning letter for presenting
a misleading promotional panel for its cardiovascular drug Coreg at an industry
conference last June.
More light may soon shine on the financial deals made between
drugmakers and pharmaceutical benefit managers (PBMs), as Maine moves closer
to implementing its PBM disclosure law.
Barr Laboratories has filed a lawsuit against the FDA in federal court to obtain
180 days of marketing exclusivity for its generic version of Aventis' Allegra-D
allergy drug.
Seattle Genetics has announced that CuraGen has exercised
its option to designate a second antigen target under the parties' existing
antibody-drug conjugate (ADC) collaboration, triggering a $1 million payment
to Seattle Genetics.
Cellular Genomics (CGI), a chemical genetics based drug discovery and development
company, has announced the completion of a key performance milestone in its
joint kinase discovery program with Serono.
Australia's adult stem cell company, Mesoblast, has announced that it had signed
an agreement for production of specialized adult stem cells, known as Mesenchymal
Precursor Cells (MPCs), to be used in human pilot clinical trials in patients
with orthopedic and cardiovascular diseases.
Scientists at SIGA Technologies and privately held TransTech Pharma (TTP) announced
the receipt of a $2.7 million challenge grant from the National Institutes of
Health (NIH) to support the development of protease inhibitors to treat orthopoxvirus
infections, such as smallpox and monkeypox.
The Indian pharmaceutical sector has begun its seismic shake-up following the
introduction of new laws granting patent protection to medicines on Jan. 1.
Vertex Pharmaceuticals and Avalon Pharmaceuticals have announced that they have
entered into a licensing agreement for the development of the investigational
agent VX-944 in oncology indications.
Swiss pharmaceuticals giant Novartis is in talks to buy German generic-drugs
maker Hexal and two of its subsidiaries for up to €4.5 billion (R35.6 billion),
the daily Die Welt reported on Tuesday.
CoTherix has announced that the underwriters of its follow-on offering have
exercised their over-allotment option to purchase an additional 250,000 shares
of common stock from CoTherix to be offered at the public offering price of
$8.90 per share.